These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 15031804)
21. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor. Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630 [TBL] [Abstract][Full Text] [Related]
22. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model. Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Orr B; Douce G; Baillie S; Parton R; Coote J Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566 [TBL] [Abstract][Full Text] [Related]
24. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Hendrikx LH; Schure RM; Oztürk K; de Rond LG; de Greeff SC; Sanders EA; Berbers GA; Buisman AM Vaccine; 2011 Sep; 29(40):6874-80. PubMed ID: 21803088 [TBL] [Abstract][Full Text] [Related]
25. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056 [TBL] [Abstract][Full Text] [Related]
27. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Isacson J; Trollfors B; Taranger J; Lagergård T Pediatr Infect Dis J; 1995 Jun; 14(6):517-21. PubMed ID: 7667057 [TBL] [Abstract][Full Text] [Related]
28. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Bergfors E; Trollfors B; Taranger J; Lagergård T; Sundh V; Zackrisson G Int J Infect Dis; 1999; 3(3):140-6. PubMed ID: 10460925 [TBL] [Abstract][Full Text] [Related]
29. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209 [TBL] [Abstract][Full Text] [Related]
30. How to make sense of pertussis immunogenicity data. Olin P; Hallander HO; Gustafsson L; Reizenstein E; Storsaeter J Clin Infect Dis; 2001 Dec; 33 Suppl 4():S288-91. PubMed ID: 11709761 [TBL] [Abstract][Full Text] [Related]
31. Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis. Frühwirth M; Wolf H; Heininger H; Guggenbichler JP; Stehr E Adv Exp Med Biol; 1995; 371B():777-83. PubMed ID: 7502896 [No Abstract] [Full Text] [Related]
32. No evidence of cross-reactivity of human antibodies to a 33-mer peptide of the alpha-gliadin component of gluten with Bordetella pertussis pertactin. He Q; Viljanen MK; Hinkkanen AE; Arvilommi H; Mertsola J; Viander M Vaccine; 2005 May; 23(25):3336-40. PubMed ID: 15837240 [TBL] [Abstract][Full Text] [Related]
33. Household contact study of Bordetella pertussis infections. Deen JL; Mink CA; Cherry JD; Christenson PD; Pineda EF; Lewis K; Blumberg DA; Ross LA Clin Infect Dis; 1995 Nov; 21(5):1211-9. PubMed ID: 8589145 [TBL] [Abstract][Full Text] [Related]
34. Identification of linear B epitopes of pertactin of Bordetella pertussis induced by immunization with whole and acellular vaccine. da Silva FR; Napoleão-Pego P; De-Simone SG Vaccine; 2014 Oct; 32(47):6251-8. PubMed ID: 25252193 [TBL] [Abstract][Full Text] [Related]
35. Japanese clinical trials with Takeda acellular pertussis vaccine. Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519 [TBL] [Abstract][Full Text] [Related]
36. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995 [TBL] [Abstract][Full Text] [Related]
37. Bordetella pertussis iron regulated proteins as potential vaccine components. Alvarez Hayes J; Erben E; Lamberti Y; Principi G; Maschi F; Ayala M; Rodriguez ME Vaccine; 2013 Aug; 31(35):3543-8. PubMed ID: 23731630 [TBL] [Abstract][Full Text] [Related]